TerminatedPhase 2NCT00070291
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Studying Angioimmunoblastic T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- Ranjana Advani, MDStanford University
- Intervention
- cyclosporine(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2011
Study locations (23)
- Stanford Cancer Center, Stanford, California, United States
- Rush-Copley Cancer Care Center, Aurora, Illinois, United States
- Hematology Oncology Associates of Illinois - Berwyn, Berwyn, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
- Hematology and Oncology Associates, Chicago, Illinois, United States
- Saint Joseph Hospital, Chicago, Illinois, United States
- Midwest Center for Hematology/Oncology, Joliet, Illinois, United States
- Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States
- North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States
- La Grange Oncology Associates - Geneva, Naperville, Illinois, United States
- Cancer Care and Hematology Specialists of Chicagoland - Niles, Niles, Illinois, United States
- Hematology Oncology Associates - Skokie, Skokie, Illinois, United States
- Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
- CCOP - Carle Cancer Center, Urbana, Illinois, United States
- Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00070291 on ClinicalTrials.govOther trials for Angioimmunoblastic T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07168317Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITLThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE3NCT06522737A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeSecuraBio
- RECRUITINGPHASE2NCT07058103Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITLThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE2NCT06756308A Study of Enasidenib in People With T-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06393738A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Arvinas Inc.
- ACTIVE NOT RECRUITINGPHASE4NCT07046182Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma ForesightZhengzhou University
- ACTIVE NOT RECRUITINGPHASE3NCT03703375Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell LymphomaCelgene